Eager to diversify its revenue away from multiple myeloma treatments, Celgene (NASDAQ: CELG) spent $7.2 billion in 2015 to acquire the promising multiple sclerosis drug candidate ozanimod. Then, it rushed ozanimod through phase 3 trials, and submitted it to the FDA.On Tuesday after the closing bell, we learned that Celgene may have moved too quickly.